Hansa Biopharma’s imlifidase, an antibody-cleaving enzyme, has yielded positive data from a pivotal U.S. Phase III trial in highly sensitized kidney disease patients. The drug rapidly removes antibodies, facilitating transplantation in patients previously considered ineligible. In the controlled trial, kidney function at 12 months post-transplant showed a highly significant improvement in the imlifidase arm compared to controls. Hansa plans a Biologics License Application submission by year-end, potentially addressing a critical unmet need in transplant medicine.